Kiran Mazumdar-Shaw was born in 1953 in Bangalore, Karnataka, to Yamini Mazumdar and (Late) Rasendra Mazumdar. She is married to John Shaw. Kiran Mazumdar-Shaw grew up in the science capital of India, Bangalore, imbibing scientific curiosity from the atmosphere around her. At school, she and her classmates were taught to think for themselves, excel in everything they do, and do things differently and creatively. She did her All India Secondary School Certificate from Bishop Cotton Girl’s High School, Bangalore, in 1968 and Pre-University Course from Mount Carmel College, Bangalore, in 1969. She obtained her B.Sc. Zoology Hons from Central College, Bangalore University in 1973 and is a Post-Graduate in Malting and Brewing from Ballarat College, Melbourne University, 1975.

Kiran Shaw is Executive Chairperson, Biocon Ltd (founded Biocon in 1978); Executive Chairperson, Biocon Biologics Ltd (2021-present) and Non-Executive Chairperson, Syngene International (2015-present). She has specialized in developing and producing therapeutic proteins and other drugs through recombinant DNA technology or genetic engineering. Through investments in cutting-edge R&D, innovative science, and differentiated technologies, she has made a difference in global health by developing high-quality biopharmaceuticals and enhancing access for patients worldwide. Kiran Mazumdar-Shaw has leveraged her bioengineering knowledge to enhance global healthcare through high-quality, affordable biopharmaceuticals. Biocon, the company she founded in 1978, has used advanced science, innovative tech platforms, and international research collaborations to develop therapies that can lower treatment costs, increase access and improve healthcare outcomes.

As the pioneer in the realm of biologics in India, Biocon has achieved many firsts in space, setting new benchmarks for the industry. The company launched India’s first indigenously produced novel monoclonal antibody, Nimotuzumab, for head & neck cancer in 2006. In the promising field of biosimilars, Biocon’s pioneering achievements began with the early launches in India of recombinant human insulin in 2004, Insulin Glargine in 2009 for treating diabetes, and Trastuzumab for the treatment of cancer in 2014. Even globally, Biocon was the first to launch the cancer drug Pegfilgrastim in the U.S. and get approval for Trastuzumab there. The company was the first non-U.S. company to have biosimilar Insulin Glargine approved in Japan. Besides enabling affordable access to biologics through biosimilars, Biocon has ensured that a larger number of patients are able to afford statins and immunosuppressants formulations by supplying high-quality Active Pharmaceutical Ingredients (APIs) to generic drug makers worldwide.

Kiran is the recipient of Padma Bhushan (2005), Padma Shri (1989), Order of Australia (2020), Knight of the National Order of the French Legion of Honour (2016), EY World Entrepreneur of the Year (2020), Othmer Gold Medal (2014), Global Economy Prize for Business (2014) and ICMR’s Lifetime Achievement Award (2019). Kiran Mazumdar-Shaw has developed a rich pipeline of affordable bio-therapeutics, which are expanding access to advanced medical solutions for chronic diseases. Besides enhancing access to essential drugs for patients on the lowest rung of the economic ladder, she is helping uncover new medical insights to address the unmet needs of patients globally.